胆石清片联合熊去氧胆酸片预防肝内胆管结石术后复发25例

目的观察胆石清片联合熊去氧胆酸片预防肝内胆管结石术后复发的效果。方法回顾分析2010年3月至2012年10月行肝内胆管结石手术患者45例的临床资料,术后对照组未口服药物,治疗组口服胆石清片联合熊去氧胆酸片,观察两组患者肝功能变化和结石复发情况。结果术后肝功能均正常,患者随访时间6月-2年,治疗组结石复发率为16．00％,对照组结石复发率为25．00％,治疗组显著优于对照组（P〈0．01）。结论肝内胆管结石术后服用胆石清片和熊去氧胆酸片预防术后结石复发安全、有效,但长期疗效尚需深入研究。     

The cell cycle inhibitor P21 promotes the development of pulmonary fibrosis by suppressing lung alveolar regeneration

The cell cycle inhibitor P21 has been implicated in cell senescence and plays an important role in the injury–repair process following lung injury. Pulmonary fibrosis (PF) is a fibrotic lung disorder characterized by cell senescence in lung alveolar epithelial cells. In this study, we report that P21 expression was increased in alveolar epithelial type 2 cells (AEC2s) in a time-dependent manner following multiple bleomycin-induced PF. Repeated injury of AEC2s resulted in telomere shortening and triggered P21-dependent cell senescence. AEC2s with elevated expression of P21 lost their self-renewal and differentiation abilities. In particular, elevated P21 not only induced cell cycle arrest in AEC2s but also bound to P300 and β-catenin and inhibited AEC2 differentiation by disturbing the P300–β-catenin interaction. Meanwhile, senescent AEC2s triggered myofibroblast activation by releasing profibrotic cytokines. Knockdown of P21 restored AEC2-mediated lung alveolar regeneration in mice with chronic PF. The results of our study reveal a mechanism of P21-mediated lung regeneration failure during PF development, which suggests a potential strategy for the treatment of fibrotic lung diseases.     

瑞舒伐他汀对高血压合并高脂血症患者血压的影响

目的 观察瑞舒伐他汀对高血压合并高脂血症患者血压的影响.方法 选择首次诊断为高血压合并高脂血症的患者120例.随机分为治疗组(58例)和对照组(62例),对照组给予常规降压药物治疗,治疗组在常规治疗基础上加用瑞舒伐他汀10mg/d口服.测定治疗前后动态血压水平,血中低密度脂蛋白胆固醇(LDL-C)、高敏C反应蛋白(hs-CRP)、血浆内皮素水平.结果 治疗1月后,两组血压均较治疗前明显降低(P<0.05),治疗组血压下降更明显(P<0.05);治疗组血中LDL-C和hs-CRP、内皮素水平较治疗前明显降低(P<0.05),与对照组比较差异也有显著性(P<0.05).结论 应用瑞舒伐他汀可降低高血压患者血中LDL-C和hs-CRP、内皮素水平,进一步降低血压.     

胰岛素和亚硒酸钠最佳配比组方研究

目的 确定普通胰岛素与亚硒酸钠降血糖作用的最佳组方配比.方法 采用小剂量链脲佐菌素腹腔注射联合高糖高脂饲养的大鼠模型,以血糖降低百分率为考察指标,根据权重配方法设不同配比组方6组,分析结果得出最佳理论配比,并进一步做确证性试验考察二者的相互关系.结果 胰岛素与亚硒酸钠对血糖的控制为协同作用,二者比例为1 U:5μg时可显著降低血糖.结论 胰岛素和亚硒酸钠的最佳配比为1 U:5μg.     

仙灵骨葆联合钙剂治疗高龄患者老年性骨质疏松症的临床研究

目的：观察仙灵骨葆胶囊联合钙尔奇D和骨化三醇对高龄患者老年性骨质疏松症的治疗效果.方法：选择60例高龄老年性骨质疏松症患者随机分为两组,治疗组（仙灵骨葆＋钙尔奇D＋骨化三醇）30例,对照组（钙尔奇D＋骨化三醇）30例.观察两组患者治疗前后和两组间的VAS评分、SF-36评分、BMD、血Ca、血P、ALP、TRACP的差异.结果：两组治疗后VAS评分较治疗前均明显降低（P＜0.01）,治疗组降低较对照组更明显（P＜0.01）.两组治疗后SF-36评分较治疗前均明显提高（P＜0.01）,治疗组升高较对照组更明显（P＜0.01）.治疗组治疗后BMD明显升高,对照组BMD变化不大,两组比较有显著差异（P＜0.05）.治疗前后两组血Ca和血P均变化不大,组间比较无差异（P＞0.05）.治疗组治疗后ALP明显升高,对照组ALP变化不大,两组比较有显著差异（P＜0.05）.两组治疗后TRACP较治疗前均有所降低,治疗组降低明显,组间比较有显著差异（P＜0.01）,两组所有患者无严重不良反应发生.结论：仙灵骨葆胶囊联合钙尔奇D和骨化三醇治疗高龄患者老年性骨质疏松症效果确切,且安全性良好.     

LOX与VEGF蛋白在人喉鳞癌中的表达及其相关性研究

目的检测赖氨酰氧化酶（LOX）、血管内皮生长因子（VEGF）蛋白在人喉鳞癌中的表达,探讨其对喉鳞癌转移及预后的影响及意义。方法采用免疫组织化学方法检测14例有淋巴结转移的喉鳞癌及24例未见淋巴结转移的原位癌组织中LOX及VEGF的表达情况,并分析其表达的相关性。结果①LOX、VEGF在喉鳞癌组织中表达显著高于癌旁正常组织（P均〈0．05）。②VEGF在淋巴结转移组与无转移组表达阳性率分别为100％和71％,具有显著性差异（P〈0．05）;LOX在淋巴结转移组与无转移组表达无显著性差异（P〉0．05）。③LOX、VEGF的表达与患者的年龄、性别、临床分型及临床分期等临床病理因素无关。④LOX与VEGF在人喉鳞癌组织中表达呈正相关。结论LOX与VEGF存在正相关性,可作为喉癌治疗的一个新靶点。VEGF的高表达可能是造成LOX表达变化的重要影响因素之一。     

人参皂苷Rg1对大脑皮质神经细胞生物膜的影响

目的:研究人参皂苷Rg1对原代培养正常大鼠大脑皮质神经细胞生物膜的影响。方法:采用细胞培养技术,运用比色法、硫代巴比妥酸法、黄嘌呤氧化酶法(羟胺法)和微量酶标法测定人参皂苷Rg1对细胞内ACP活力、MDA含量、SOD活力及LDH释放量的影响。结果:1mg/ml、2 mg/ml及4 mg/ml人参皂苷Rg1作用30min可不同程度增加正常培养神经细胞的LDH释放量和细胞内SOD活力,降低细胞内ACP活力及MDA含量。结论:1mg/ml、2 mg/ml及4 mg/ml人参皂苷Rg1作用30min对正常培养大脑皮质神经细胞生物膜具有显著影响,其中对溶酶体膜有保护作用,对生物膜的脂质过氧化反应有抑制作用,能减轻自由基对生物膜的攻击及损伤,但对细胞膜可能有一定的损伤作用。     

Flavonoids in myocardial ischemia–reperfusion injury: Therapeutic effects and mechanisms

Ischemic heart diseases are one of the major causes of death worldwide. Effective restoration of blood flow can significantly improve patients’ quality of life and reduce mortality. However, reperfusion injury cannot be ignored. Flavonoids possess well-established antioxidant properties;They also have other benefits that may be relevant for ameliorating myocardial ischemia-reperfusion injury(MIRI). In this review,we focus on flavonoids with cardiovascular-protection function and emphasize their pharmacological effects. The main mechanisms of flavonoid pharmacological activities against MIRI involve the following aspects: a) antioxidant, b) anti-inflammatory, c) anti-platelet aggregation, d) anti-apoptosis, and e)myocardial-function regulation activities. We also summarized the effectiveness of flavonoids for MIRI.